

COF<sup>2</sup>

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 6,924,286 ) Serial No. 10/633,376  
Inventor(s): Michael L. VAZQUEZ *et al* ) Filed: August 4, 2003  
Issue Date: August 2, 2005 ) Attorney Docket No. 101765.00142

For:  $\alpha$ - AND  $\beta$ -AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS  
RETROVIRAL PROTEASE INHIBITORS

**REQUEST FOR CERTIFICATE OF CORRECTION**

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop: Certificate of Correction Branch  
401 Dulany Street  
Alexandria, VA 22314

**Certificate**  
**MAR 08 2006**  
**of Correction**

Sir:

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, this is a request for the issuance of a Certificate of Correction in the above-identified patent. Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves one page.

The mistakes identified in the appended Form occurred through no fault of the Applicants, as clearly disclosed by the records of the application, which matured into this patent. Enclosed for your convenience are the relevant portions of the Supplemental Preliminary Amendment filed February 3, 2004.

Issuance of the Certificate of Correction containing the corrections is respectfully requested. Since these changes are necessitated through no fault of the Applicants, no fee is believed to be associated with this request. Nonetheless, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By: 

Joseph M. Skerpon  
Registration No. 29,864

Dated: March 6, 2006

1001 G Street, N.W. (11th Fl.)  
Washington, D.C. 20001  
(202) 824-3000

MAR 8 2006


UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,924,286  
DATED: August 2, 2005  
INVENTOR(S): Michael L. VAZQUEZ *et al*


It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 235, Claim 6, Line 19:  
Please replace "iso-amyl" with --iso-amyl,--

In Column 238, Claim 18, Line 20:  
Please replace the following formula"



with the below formula



Mailing Address of Sender:

Banner & Witcoff, Ltd.  
11th Floor  
1001 G Street, N.W.  
Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)

U.S. PAT. NO 6,9254,286

8 2005

No. of add'l copies  
@ \$0.50 per page

□


UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,924,286  
DATED: August 2, 2005  
INVENTOR(S): Michael L. VAZQUEZ *et al*


It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 235, Claim 6, Line 19:  
Please replace "iso-amyl" with --iso-amyl,--

In Column 238, Claim 18, Line 20:  
Please replace the following formula"



with the below formula



Mailing Address of Sender:

Banner & Witcoff, Ltd.  
11th Floor  
1001 G Street, N.W.  
Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)

U.S. PAT. NO 6,9254,286

No. of add'l copies  
@ \$0.50 per page

□



☒ PATENT ☐ DESIGN B&W Ref. 101765/00142 Date 2-3-04

☒ HAND CARRY Group/Section

Serial/Patent No. 101765/00142

Inventor Van Ghezel

Bldg

Rm

Atty/Sec

Client

JMS/BCS/vlh

Title

Anti-B-2 Aminic Acid Hydroxyethylamine

Spirobenzimidazole Use for HS Retroviral Protease Inhibitors

The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:

☐ Total pp Spec. including: # of Claims

☐ (# of independent claims) ☐ Abstract

☐ Drawings: ☐ Formal ☐ Informal

☐ (# of distinct sheets) ☐ Figs

☐ Declaration/Power of Attorney: ☐ Executed ☐ Unexecuted

☐ Assignment w/PTO Cover Sheet

☐ IDS w/PTO 1449 ☐ References ☐ w/Fee

☒ Preliminary Amendment ☒ Supplemental

☐ Priority Claim (Foreign or U.S. Provisional B&W #)

Country

☐ w/Foreign Priority Document(s)

Applicant: ☐ CIP ☐ Continuation ☐ Divisional

Parent Ser. No. B&W#

☐ U.S. Provisional pp Spec/Claims; Cover Sheet

☒ Response to Missing Parts/Requirements dt 11-3-03

☐ Response to Notice to File Corrected Appn. Papers dt

☐ Request for Expedited Foreign Filing License

☐ Request for Corrected: ☐ Filing Receipt ☐ Assignment

☐ Response to Restriction/Election Requirement

☐ Sequence Listing: ☐ Diskette ☐ Paper

☐ Amendment ☐ Response: OA dt

☒ Petition for Extension of Time until 2-3-04

☐ CPA ☐ RCE ☐ w/Ext of Time: OA dt

☐ Request for Approval of Drawing Changes

☐ Notice of Appeal & Fee

☐ Brief ☐ Appeal & Fee ☐ Reply

☐ Request for Oral Hearing

☐ Issue Fee ☐ Advance Patent Copies (# ordered)

☐ Notice of Allowance dt

☐ Amendment under 37 CFR 1.312

☐ Request for Certificate of Correction

☐ Transmittal ☒ Fee Transmittal w/Auth. to Charge Deposit Acct

☐ Certificate of Mailing

☐ Check # for \$

☒ \$ 1010 - Total Fees

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

B&W Rev 501

BEST AVAILABLE COPY



$R^1$  is a hydrogen, alkyl or aralkyl; and  $R^{1'}$  is a hydrogen, alkyl,  $-\text{CO}_2\text{CH}_3$  or  $-\text{CONH}_2$ ; or one of  $R^1$  and  $R^{1'}$  together with  $R^1$  and the carbon atoms to which  $R^1$ ,  $R^{1'}$  and  $R^{1''}$  are attached, form a cycloalkyl radical;


with the proviso that alkyl, alone or in combination, is a straight-chain or branched-chain hydrocarbon radical containing from one to five carbon atoms; alkenyl, alone or in combination, is a straight-chain or branched-chain hydrocarbon radical having at least one double bond and containing from two to five carbon atoms; alkynyl, alone or in combination, is a straight-chain or branched-chain hydrocarbon radical having at least one triple bond and containing from two to five carbon atoms; and cycloalkyl, alone or in combination, is a hydrocarbon ring containing from three to eight carbon atoms; ~~and with the proviso that when  $R^2$  is cycloalkylalkyl and  $t$  is 0,  $R^1$  is a group other than alkoxy carbonyl.~~

6. (amended) The compound of claim 5 or a pharmaceutically acceptable salt or ester thereof, wherein

~~$R^2$  is butyl, cyclohexylmethyl, benzyl, 4-fluorobenzyl or naphthylmethyl;~~


$R^3$  is methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-butyl, ~~iso-amyl~~, 3-methoxypropyl, 3-methylthiopropyl, 4-methylthiobutyl, 4-methylsulfonylbutyl, 2-dimethylaminoethyl, 2-(1-morpholino)ethyl, 4-hydroxybutyl, allyl, propargyl, cyclohexylmethyl, cyclopropylmethyl, phenyl, benzyl, 4-fluorobenzyl, 4-methoxybenzyl, 1-phenylethyl, 2-phenylethyl, naphthylmethyl, 3-pyridylmethyl or 4-pyridylmethyl;

21. (new) The compound of claim 1, represented by the formula:



wherein  $R^3$ ,  $R^4$ ,  $R^6$ ,  $x$ ,  $Y$ , and  $A$  are as defined in claim 1.

22. (new) The compound of claim 8, represented by the formula:



wherein  $P^1$ ,  $P^2$ ,  $R^3$ , and  $R^4$  are as defined in claim 8.

23. (new) A pharmaceutical composition comprising a compound of Claim 21 and a pharmaceutically acceptable carrier.